Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases by unknown
Interferon-y-inducible  Protein  10  (IP-10)  Is an Angiostatic 
Factor That Inhibits Human  Non-small Cell Lung  Cancer 
(NSCLC) Tumorigenesis  and  Spontaneous  Metastases 
By Douglas A. Arenberg,* Steven L. Kunkelfl Peter  J. polverini,~ 
Susan B. Morris,* Marie D. Burdick,* Mary C. Glass,* Dennis T.Taub,II 
Mark D. Iannettoni,￿82  Richard I.Whyte,￿82  and Robert M. Strieter* 
From the *Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, 
University of Michigan Medical School,  Ann Arbor, Michigan 48109-0360; ~-Section of Oral 
Pathology, University of Michigan Dental School,  Ann Arbor, Michigan 48109-1078; ~  Department 
of Pathology, University of Michigan, Ann Arbor, Michigan 48109; flLaboratory of Molecular 
Immunoregulation, National Cancer Institute, Frederick, Maryland 21702; ￿82  of Surgery, 
Section of Thoracic Surgery, University of Michigan, Ann Arbor, Michigan 48109 
Summary 
The success of solid tumor growth and metastasis is dependent upon angiogenesis. Neovascu- 
larization within the tumor is regulated, in part, by a dual and opposing system of angiogenic 
and angiostatic factors. We now report that IP-10, a recently described angiostatic factor, is a 
potent angiostatic factor that regulates non-small cell lung cancer (NSCLC)-derived angiogen- 
esis, tumor growth, and spontaneous metastasis. We initially found significantly elevated levels 
of IP-10 in freshly isolated human NSCLC samples of squamous cell carcinoma (SCCA).  In 
contrast, levels of IP-10 were equivalent in either normal lung tissue or adenocarcinoma speci- 
mens. The neoplastic cells in specimens of SCCA were the predominant cells that appeared to 
express IP-10 by immunolocalization. Neutralization of IP-10 in SCCA tumor specimens re- 
sulted in enhanced tumor-derived angiogenic activity. Using a model of human NSCLC tum- 
origenesis in SCID mice, we found that NSCLC tumor growth was inversely correlated with 
levels of plasma or tumor-associated IP-10.  IP-10 in vitro functioned as neither an autocrine 
growth factor nor as an inhibitor of proliferation of the NSCLC cell lines, tkeconstitution of 
intratumor IP-10 for a period of 8 wk resulted in a significant inhibition of tumor growth, tu- 
mor-associated angiogenic  activity and  neovascularization,  and  spontaneous  lung metastases; 
whereas, neutralization  of IP-10 for 10 wk augmented tumor growth. These findings support 
the notion that tumor-derived IP-10 is an important endogenous angiostatic factor in NSCLC. 
L 
ung cancer is responsible for ~150,000  deaths per year 
in  the  US  (1-3).  Treatment  protocols  for  non-small 
cell lung cancer (NSCLC) 1 currently yield an overall 5 yr 
survival rate of 15% (1, 4). To develop more effective ther- 
apy,  further  insights  into  the  biology of NSCLC  are  re- 
quired. NSCLC, similar to other solid tumors, is dependent 
upon  neovascularization  to  continually  supply the  tumor 
with nutrients  and oxygen  (5,  6).  Investigations of tumor 
angiogenesis have primarily focused on the  role of angio- 
genic  factors,  such  as  vascular  endothelial  growth  factor 
1Abbreviations used in this paper: BCE, bovine adrenal gland capillary en- 
dothelial cells; bFGF, basic fibroblast growth factor; HPF, high power 
fields; 1P-10, interferon-'y-inducible  protein 10; MIG, monokine induced 
by interferon-gamma;  NSCLC, non-small  cell lung cancer; SCCA, squa- 
mous cell carcinoma; VEGF, vascular  endothelial growth factor. 
(VEGF),  interleukin-8  (IL-8), transforming growth  factor 
[3 (TGF[~),  and basic fibroblast growth factor (bFGF) (7-10). 
However, recent studies  have demonstrated  an increasing 
role for endogenous angiostatic factors in the regulation of 
net tumor-associated neovascularization.  For example, the 
loss of endogenous angiostatic molecules may contribute to 
the  augmentation  of tumor-associated angiogenic  activity 
that enhances tumorigenesis and potential spontaneous me- 
tastasis  (11-14).  This  suggests  that  overall  tumor-derived 
neovascularization  is  regulated  by  an  imbalance  in  the 
expression  of angiogenic  and  angiostatic  factors  present 
within the tumor. 
Historically, interferons have been shown to inhibit tu- 
mor growth and wound repair (15,  16).  One of the mech- 
anisms for this effect appears to be related to  their anglo- 
static properties (17-19).  Interferon-y-inducible protein 10 
(IP-10)  is a CXC  chemokine produced by a wide variety 
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and  others have  recently identified that  IP-10  is a  potent 
angiostatic factor  (24-27),  suggesting that  IP-10 may be  a 
distal mediator of the angiostatic effects ofinterferons. 
We  postulated  that  IP-10  is  an  important  endogenous 
inhibitor of angiogenesis in  human  NSCLC.  To  test  this 
hypothesis, we initially isolated fresh specimens of human 
NSCLC, and found that squamous cell carcinoma (SCCA), 
as  compared  to  either  normal  lung  tissue  or  adenocarci- 
noma  specimens,  was  associated  with  increased  levels  of 
IP-10. Neutralization of IP-10 from these samples demon- 
strated that IP-10 behaved as a potent endogenous inhibi- 
tor of SCCA-derived angiogenic activity. To extend these 
observations to an in vivo model system, a human NSCLC/ 
SCID  mouse  chimera  was  employed by injecting human 
NSCLC  cell  lines,  A549  (adenocarcinoma)  and  Calu  1 
(squamous  cell carcinoma), into  the flanks of SClD  mice. 
We found that the production of tumor-derived IP-10 was 
inversely correlated with the rate of growth of the two hu- 
man NSCLC cells lines. IP-10 functioned as neither an au- 
tocrine growth fhctor nor as an inhibitor of in vitro prolif- 
eration  of the  NSCLC  cell  lines.  Moreover,  an  in  vivo 
strategy to  reconstitute  intratumor  IP-10,  by injecting tu- 
mors with  recombinant  human  IP-10,  as compared to  an 
equimolar  concentration  of an  irrelevant  human  protein, 
resulted in a  decrease in tumorigenesis, tumor-derived an- 
giogenic activity and  neovascularization, and  spontaneous 
lung metastases. This effect was unrelated to any alteration 
of tumor  infiltrating leukocytes.  Moreover,  depletion  of 
IP-10  for  10  wk  resulted  in  augmented  tumor  growth. 
These findings suggest that IP-10 is an important endoge- 
nous  angiostatic  factor  in  human  NSCLC,  specifically 
SCCA, and illustrates a potential strategy to correct the im- 
balance ofangiogenic activity in human NSCLC. 
Materials  and Methods 
Reagents.  Polydonal rabbit anti-human  IP-10 sera was pro- 
duced by inmmnization of rabbits with recombinant human IP-10 
(Peprotech,  Rocky  Hill, NJ)  in multiple intradermal sites  with 
complete  Freund's adjuvant.  The  specificity of the  IP-10  anti- 
serum was  confirmed by ELISA and Western blot analysis,  and 
was not cross-reactive with a panel of 12 other recombinant hu- 
man cytokines or the murine chemokines KC and MIP-2. In ad- 
dition, this antisera recognized both murine and human forms of 
IP-10 using Western blot analysis, and was endotoxin-free. [Lab- 
bit anti-Factor VIII-related antigen antibodies used  for  FACS  | 
analysis  of tumor-associated  vasculature  were  purchased  from 
Biomeda (Foster City, CA). Rabbit anti-murine macrophage and 
neutrophil antibodies were purchased from Accurate Antibodies 
(Westbury, Nu  A549 (adenocarcinoma)  cell culture media con- 
sisted of 1LPMI-1640 (Whitaker Biomedical Products, Whitaker, 
CA) supplemented with 1 mM glutamine, 25 mM Hepes buffer, 
100 U/nil penicillin, 100 ng/nil streptomycin, and 10% fetal calf 
serum.  Calu  1  (SCCA)  cell culture  media consisted of Eagle's 
minimal essential medium, supplemented with 1 mM glutamine, 
25  mM  Hepes buffer,  100  U/ml penicillin, 100  ng/ml strepto- 
mycin,  1% sodium pyruvate,  1% non-essential amino acids,  and 
10%  fetal calf serum.  The  "anti-protease" buffer for tissue  ho- 
mogenization consisted of 1 ￿  PBS with 2 mM phenylmethylsul- 
fonyl fluoride, and I  p~g/ml each of antipan, aprotinin, leupeptin, 
and pepstatin A. 
Normal Human Lung and NSCLC Tumor Tissue.  Tissue  spec- 
imens were obtained from consented individuals undergoing tho- 
racotomy (n = 90)  for suspected NSCLC in accordance with the 
University of Michigan I.R.B. approval. Samples of tumor, and 
normal lung distal to tumor, were homogenized and sonicated in 
"anti-protease" buffer upon recovery from the operating room. 
Specimens were centrifuged at 900 g for 15 min, filtered through 
0.45  I~m Sterile Acrodiscs (Gelman  Sciences, Ann  Arbor, MI), 
and fiozen at  -70~  until thawed for assay by a specific IP-10 
ELISA. A portion of this specimen was used for the in vitro en- 
dothelial  cell  chemotaxis  assay;  and  another  portion  was  lyo- 
philized (SpeedVac;  Savant,  Farmingdale, NY), normalized to an 
equivalent amount of total protein, and used in the corneal mi- 
cropocket model of neovacularization for analysis of angiogenic 
activity. Additionally, a portion of tumor was also  fixed in  4% 
paraformaldehyde and imbedded in paraffin for histologic and im- 
munohistochemical analysis. Histologic determination of NSCLC 
cell type was provided by University of Michigan Pathologists. 
Only cases of NSCLC were included in our analysis,  (squamous 
cell carcinoma, n =  40;  adenocarcinoma, n =  50).  Normal lung 
tissue  was  examined histologically and used as a control only if 
the  histology appeared nonnal  without  evidence for inflamma- 
tion or malignant cell invasion (n = 49). 
IP-IO ELISA.  Antigenic IP-10 was quantitated using a mod- 
ification of a double ligand method as previously described (28, 
29).  Briefly, flat-bottomed 96-well microtiter plates (Nunc  hn- 
nmno-Plate I 96-F; Fisher Scientific, Pittsburgh, PA) were coated 
with 50 ~l/well of the polyclonal anti-IP-10 (1  ngtp~l in 0.6 M 
NaC1,  0.26  M  H~B04, and 0.(18 N  NaOH,  pH 9.6)  for 24  h  at 
4~  and then washed with phosphate-buffered saline (PBS),  pH 
7.5,  0.05%  Tween-20 (wash buffer).  Microtiter plate nonspecific 
binding sites were blocked with 2% BSA in  PBS  and incubated 
for  60  rain at  37~  Plates were  rinsed three  times with  wash 
buffer.  50 ~1 of either tumor bomogenate or plasma were added 
(neat and 1:10 dilution), followed by incubation for 1 h at 37~ 
Plates were washed three times, 50  hal/well of biotinylated poly- 
clonal  rabbit  anti-IP-10  (3.5  ng/bd  in  PBS,  pH  7.5,  0.05% 
Tween-20, and 2% FCS) added, and plates incubated for 45 rain 
at 37~  Plates were washed three times, streptavidin-peroxidase 
conjugate  (Bio-P,  ad  Laboratories, FZichmond,  CA)  added,  and 
the plates incubated for 30 rain at 37~  Plates were washed three 
times  and  chromogen  substrate  (Bio-P,  ad  Laboratories)  added. 
The plates were incubated at room temperature to the desired ex- 
tinction,  and  the  reaction terminated with  50  IM/well of 3  M 
H2SO 4 solution. Plates were read at 490 nm in an automated mi- 
croplate  reader  (Bio-Tek  Instruments,  Inc.,  Winooski,  VT). 
Standards were dilutions oflP-10 from 100 ng/ml to 1 pg/mt (5(1 
D1/well).  This  protocol consistently detected  IP-10  concentra- 
tions greater than  50  pg/nil in  a linear fashion.  Tissue samples 
were run in parallel for total protein (TP) content (Pierce Chem. 
Co., Rockford, IL), and results expressed as ng oflP-10 per nag TP. 
hnmunolocalization oflP-IO Protein.  IP-10 protein was inmm- 
nolocalized in paraffin-embedded human  NSCLC  tissue  using a 
modification  of our  previously  described  technique  (3(/, 31). 
Briefly, paraffin-embedded tissue  sections were  de-waxed with 
xylene, and rehydrated through graded concentrations of ethanol. 
Nonspecific protein binding sites were blocked using normal goat 
serum (BioGenex, San  1Kamon, CA). Tissue sections were then 
washed and incubated with 1:1,000  diluted rabbit anti-IP-10 se- 
ruin, or an equivalent dilution of control antisera. The tissue sec- 
982  IP-10 as an Endogenous Angiostatic Factor in Non-small Cell Lung Cancer tions were washed and then incubated for 60 rain with biotiny- 
lated goat anti-rabbit antibodies (BioGenex). Sections were then 
washed twice in TRIS-buffered saline and incubated with alka- 
line phosphatase conjugated to streptavidin (BioG6nex). Fast Red 
(BioGenex) reagent was used for chromogenic localization oflP-10 
antigen. After  optimal  color development,  tissue  sections  were 
immersed in sterile water,  counter-stained with Mayer's hema- 
toxylin, and cover slipped using an aqueous mounting solution. 
Endothelial Cell Chemotaxis Assay.  Endothelial cell  chemotaxis 
was performed in 48-well, blind well chemotaxis chambers (Co- 
star Corp., Cambridge, MA) as previously described (32). Briefly, 
bovine adrenal gland capillary endothelial cells (BCE)  were  sus- 
pended at  a  concentration of 106  cells/nil in DME  with  0.1% 
BSA and placed into each of the bottom wells (25  nil). Nude- 
opore  chemotaxis  membranes (5  b~m pore  size)  were  first  pre- 
pared by soaking in 3% acetic acid for 12 h, followed by coating 
for 2  h  in gelatin (0.1  mg/ml).  The membranes were  rinsed in 
sterile  water,  dried  under  a  laminar flow  hood,  and  stored  at 
room temperature for up to  1 mo. The membranes were placed 
over the wells, chambers sealed, inverted, and incubated for 2 h 
to allow cells  to adhere  to the membrane. Chambers were  then 
reinverted, and 50 ml of human NSCLC tumor homogenates nor- 
malized to TP and pre-incubated in the presence of either 1:1,000 
dilution of control or neutralizing rabbit anti-human IP-10 anti- 
bodies were placed in the top wells and reincubated for an addi- 
tional 2 h. Membranes were then fixed in methanol, stained with 
a Diff-Quick staining kit (American Scientific Products), and the 
cells which had migrated through the membrane were counted in 
ten high power fields (HPF; 400￿  Results were expressed as the 
number of endothelial  cells  that  had  migrated  per  HPF.  Each 
sample  was  assessed  in triplicate.  Experiments were  repeated  at 
least three times. 
Corneal Micropocket Assay qf Angiogenesis.  Angiogenic  activity 
of NSCLC tumor homogenates was assayed  in vivo in the avas- 
cular cornea of hooded Long-Evans female rat eyes, as previously 
described  (33,  34).  Briefly,  equal volumes of lyophilized tunmr 
specimens normalized to total protein, were combined with ster- 
ile Hydron (Interferon Sciences Inc., New Brunswick, NJ)  cast- 
ing solution. 5-1*1 aliquots were pipetted onto the flat surface of 
an inverted sterile polypropylene specimen container, and poly- 
merized overnight in a laminar flow hood under UV light. Before 
implantation, pellets were rehydrated with normal saline. Animals 
were anesthetized with ketamine (150 mg/kg) and atropine (250 
btg/kg) i.p. Rat corneas were anesthetized with 0.5% proparacaine 
hydrochloride  ophthalmic solution followed by implantation of 
the Hydron pellet into an intracorneal pocket  (1  to 2  mm from 
the limbus). 6 d  after implantation, animals received  1,000 U  of 
heparin and ketamine (150 mg/Kg) i.p., followed by a 10-ml perfu- 
sion of colloidal carbon via the left ventricle. Corneas were harvested 
and photographed.  No  inflammatory response  was  observed in 
any of the  corneas  treated  with  the  above  specimens.  Positive 
neovascularization responses were  recorded  only if sustained di- 
rectional ingrowth of capillary sprouts and hairpin loops towards 
the implant were observed. Negative responses were recorded when 
either no growth was observed or when only an occasional sprout 
or hairpin loop displaying no evidence of sustained growth was 
detected. All animals were handled in accordance with the Uni- 
versity of Michigan unit for laboratory animal medicine (ULAM). 
Human NSCLC Cell Lines.  The A549 (adenocarcinoma) and 
Calu i  (squamous cell carcinoma) cell lines (American Type Cul- 
ture  Collection, Rockville, MD)  were maintained in sterile  150 
cm  2 tissue culture flasks. Cells were cultured and passaged at 37~ 
in room air/5% CO2. For proliferation assays, 2  ￿  103 cells were 
plated in each  well of a  96-well plate and allowed to  grow for 
24 h, serum starved for 24 h, then treated with varying concen- 
trations oflP-10 in media with 1% serum. After 24 and 48 h, cells 
were  then quantitated using a  non-radioactive cell proliferation 
assay  according to  the  manufacturers instructions (CellTiter 96 
AQ; Promega Corp., Madison, WI) and using a standard (0,  103, 
2  X  103, 5  X  103, 7.5 X  103, 104, 2.0 X  104, 2.5 ￿  104, 5  X  104, 
7.5 ￿  104, 1 X  10s'2 ￿  10 s) of NSCLC cells on the day of assay. 
For inoculation into mice, the cells  were  trypsinized, harvested, 
washed, and resuspended in serum-free media at a concentration 
of 1 X  10  v cells/ml. 
Human NSCLC-SCID Mouse Chimeras.  4-6-wk-old  female 
CB17-SCID mice (Taconic Farms, Germantown, NY)  with se- 
rum  Ig  <1  ~g/ml  were  injected subcutaneously with  human 
NSCLC cells  (1  ￿  106 cells in 100 ~1) into each flank. The ani- 
mals  were  maintained under sterile  conditions in laminar flow 
rooms. Tumor-bearing mice were killed at weekly intervals (n = 
6 per wk). At time of death, anticoagulated (heparin 50 U/500 I.zl 
of blood)  blood  was  collected  and  centrifuged.  The  isolated 
plasma was stored at -70~  for later analysis.  In addition, at time 
of death  tumors  were  dissected  from  the  mice,  weighed,  and 
measured  with  a  Thorpe  caliper  (Biomedical  Research  Instru- 
ments,  Rockville,  MD).  The  lungs  were  inflated  with  4% 
paraformaldehyde, and fixed in paraffin.  In the  IP-10 treatment 
studies, mice received intra-tumor injections of either human re- 
combinant IP-10 (1  ~g in 20 btl of sterile saline every other day) 
or an equimol~/r concentration of an irrelevant protein  (human 
serum albumin; HSA)  beginning at the  time of tumor inocula- 
tion. In the  IP-10 depletion studies, SCID mice received intra- 
peritoneal injections of 500 I*l of either neutralizing rabbit anti- 
human IP-10 or control (pre-immune) serum every 48 h  for 10 
wk, starting at the time of cell inoculation. All animals were han- 
dled in accordance with ULAM. 
Processing of SCID/NSCLC Tumor Specimens.  Human NSCLC 
tumor  specimens  from  SCID  mice  were  processed  as  follows. 
One portion was homogenized and sonicated in "anti-protease" 
buffer, centrifuged at 900 g for 15 nfin, filtered through 0.45 ~m 
Sterile Acrodiscs  (Gelman Sciences), and frozen at  -70~  until 
thawed for assay by a specific IP-10 ELISA. Another portion was 
fixed in 4% paraformaldehyde for histologic analysis and immu- 
nohistochemistry. The  final portion of tumor was  minced into 
<1 mm  3 sections and incubated for 1 h in protease digestion me- 
dia (Dispase,  Collaborative Biomedical Products, Two Oak Park, 
MA). Cells were then pelleted at 600 g for 10 rain, red blood cells 
lysed, washed in PBS, and resuspended in complete media with 
5% FCS. Cells were counted, and transferred to fluorescent anti- 
body buffer (1% FA buffer; Difco Detroit, MI, 1% FCS, and 0.1% 
azide, 5  ￿  10  ~' cells/nil) and maintained at 4~  for the remainder 
of the staining procedure. 100 b~l of tumor cells were labeled with 
rabbit anti-Factor VIII-related antigen antibodies to recognize tu- 
mor-associated  endothelial  cells.  Pre-immune  rabbit-IgG  was 
used as a control. FITC-conjugated goat anti-rabbit IgG was used 
as a secondary antibody. FACS  |  analysis was  then employed to 
detect Factor VIII-related antigen expressing cells. Tumor vascu- 
lature was expressed as the percentage of cells from the tumor that 
were positive for Factor VIII-related antigen. 
Quantitation of Infiltrating Leukocytes.  Leukocytes  were  local- 
ized  and  quantitated  in  human  NSCLC  tumor/SCID  mouse 
specimens treated with either IP-10 or HSA using a modification 
of our previously described method  (30,  31). Briefly, tissue sec- 
tions were de-waxed with xylene, and rehydrated through graded 
concentrations of ethanol. Nonspecific protein binding sites were 
blocked  using  normal  goat  serum  (BioGenex).  Sections  were 
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Figure  1.  NSCLC-derived 1P-10 protein. IP-10 measured from either 
normal  lung tissue,  NSCLC  (combined specimens  of adenocarcinoma 
[Adeno] and squamous cell carcinoma [SCCA]), adeno (n = 50) or SCCA 
(n = 40) cell-types  ofNSCLC.  IP-10 is expressed as ng/mg of total pro- 
tein (TP). 
then washed and incubated with either rabbit anti-murine mac- 
rophage  (1:1,000),  rabbit anti-murine neutrophil antisera (1:1,000), 
or an equivalent dilution of control antisera.  The  tissue sections 
were  washed  and  then  incubated for  60  rain  with biotinylated 
goat  anti-rabbit  antibodies  (BioGenex).  Sections  were  then 
washed twice in TRIS-buffered  saline and incubated with alka- 
line phosphatase conjugated to streptavidin (BioGenex). Fast Red 
(BioGenex)  reagent  was  used  for  chromogenic  localization  of 
routine leukocytes.  After optimal color development,  tissue sec- 
tions  were  immersed  in  sterile  water,  counter-stained  with 
Mayer's hematoxylin, and cover slipped using an aqueous mount- 
ing solution.  Tumor  sections were  then examined under 200￿ 
magnification and cells counted.  A  total of five fields per tumor 
section,  six  sections  per  tumor,  and  six  tumors  per  treatment 
group  were  counted.  Results  were  expressed  as  the  number of 
leukocytes per high power field (200￿ 
Quantitation of Lun  2 Metastases by Light Microscopy.  Six  H&E 
stained lung sections from each lung of SCID  mice treated with 
either  intratumor  IP-10  or  HSA  for  8  wk  (n  =  6  animals  per 
group)  were  examined under low  magnification  (40￿  for  evi- 
dence of spontaneous metastases and counted.  In addition, using 
an Olympus BH-2 microscope coupled to a Sony 3CCD  camera 
Figure 2.  Representative photomicrographs of 
the  immunolocalization  of  IP-10  in  squamous 
cell  carcinoma  (SCCA).  A,  C,  and  E  represent 
control staining of SCCA with pre-immune anti- 
bodies  (200￿  B,  D,  and  F  represent  staining 
with anti-lP-10 antibodies (200￿ 
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and a Macintosh Ilfx computer the total area of metastatic tumor 
burden  per lung section was  quantitated  using NIH Image  1.55 
software. Data were expressed as either the number of metastases 
per  lung  section  or  the  area  of metastatic  tumor  per  section 
(square pixels at 40X  magnification). 
Statistical Analysis.  The  animal  studies  involved a  minimum 
of 12 human NSCLC tumors or 6 SCID mice at each time point 
or for each manipulation.  Groups of data were evaluated by anal- 
ysis  of variance  to  indicate  groups  with  significant  differences. 
Data that appeared statistically significant were compared by Stu- 
dent's  t  test  for  comparing  the  means  of multiple  groups,  and 
were  considered  significant if P  values were less  than  0.05.  The 
Mann-Whitney  U  test was  used  to  compare groups  of observa- 
tions which were not normally distributed.  Results are presented 
as means •  SEM. Data was analyzed by Macintosh Ilfx computer 
using Statview 4.5 statistical software package  (Abacus Concepts, 
Inc.). 
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Figure 3.  Angiogenic activity from fleshly isolated SCCA. (/) Angio- 
genic response in the rat corneal  micropocket assay to SCCA homoge- 
nates pre-incubated  with either NRS (A and  B, 25X  and 50￿  respec- 
tively) or rabbit  anti-IP-10  (C and  D, 25X  and  50X,  respectively).  (I/) 
Endothelial  cell chemotactic  activity of SCCA in the presence  of either 
rabbit anti-lP-10 antibodies or NRS. Interleukin-8  (IL-8; 50 ng/ml) was 
used as a positive control. Control is DME with 0.1% BSA alone. 
Results 
IP-10 Is Significantly  Elevated in Human NSCLC.  To  de- 
termine  whether  IP-10  protein  was  present  in  human 
NSCLC,  freshly  isolated  specimens  of bronchogenic  tu- 
mors  were  assessed  by  specific  IP-10  ELISA  (Fig.  1).  The 
levels  of  IP-10  from  tumor  specimens  were  significantly 
higher than  in normal  lung tissue  (1.11  •  0.39  vs.  0.23  -+ 
0.07  ng/mg  TP,  P  <0.05).  To  ascertain  whether  the pres- 
ence of IP-10 protein varied by histol0gic cell-type, results 
were further subdivided  by cell-type  (SCCA vs.  adenocar- 
cinoma).  The  increase  in  IP-10  from  NSCLC  tissue  was 
entirely attributable  to the higher levels of IP-10 present in 
SCCA,  as  compared  to  adenocarcinoma  (2.25  +  0.83  vs. 
0.19  +  0.06 rig/rag TP,  P  <0.05,  Fig.  1). Immunolocaliza- 
tion  of  IP-10  protein  within  SCCA  specimens  revealed that the predominant cellular source of IP-10 was the neo- 
plastic ceils  (Fig. 2). 
IP-IO  Is  an  Endogenous Angiostatic  Factor in  NSCLC 
(SCCA).  While  the  above  experiments  demonstrated 
that  IP-10 protein  was  significantly elevated  in  specimens 
of fleshly isolated SCCA, we postulated that IP-10 may be 
acting in vivo to regulate  tumor-derived angiogenesis.  To 
test  this  hypothesis,  we preincubated  specimens of human 
SCCA normalized to TP in the presence of either control 
or neutralizing antibodies to IP-10 and assessed their angio- 
genic  activity using either in vivo corneal  neovasculariza- 
tion or in vitro endothelial cell  chemotaxis (Fig. 3, I and II, 
respectively).  SCCA samples  preincubated  with  neutraliz- 
ing  IP-10  antibodies,  as  compared  to  control  antibodies 
demonstrated a significant increase in their endothelial  cell 
chemotactic  activity (85.0 _  8.0 vs.  48.0  +  3.0  cells/hpf, 
P  <0.05)  (Fig. 3 I/). These findings were further confirmed 
using the in vivo rat corneal micropocket assay of neovas- 
cularization,  as SCCA specimens preincubated in the pres- 
ence of neutralizing antibodies to IP-10 (Fig. 3/,  C and D, 
at a magnification of 25￿  and 50￿  respectively), as com- 
pared to control antibodies (Fig. 3 I, A  and B, at a magnifi- 
cation  of 25￿  and  50￿  respectively),  demonstrated  an 
augmented neovascular response in the cornea. 
7t~e Production of lP-l O Inversely Correlates with Tumorigenesis 
of Human NSCLC in SCID Mice.  The  above  findings  sug- 
gested that  IP-10 represents  an important  endogenous an- 
giostatic  factor in  freshly isolated  NSCLC  (SCCA)  of the 
lung. However, to determine if this angiostatic activity was 
physiologically relevant during the course of in vivo tumor 
growth,  a human NSCLC/SCID mouse model of human 
NSCLC  tumorigenesis  was  employed.  SCID  mice  were 
inoculated  with  either  A549  (adenocarcinoma)  or Calu  1 
(SCCA) cells  (1  +  10  ~' cells/flank) and killed weekly begin- 
ning with the second and third week of tumor growth, re- 
spectively.  The experiments  using A549  cells  were  termi- 
nated  at  8  wk  due  to  morbidity  noted  in  the  animals 
secondary to  tumor burden.  As shown  in  Fig.  4  A,  there 
was  a  progressive  increase  in  tumor size  in  A549-bearing 
animals beginning at week 2  through week 8.  In contrast, 
animals bearing Calu  1 tumors demonstrated little  growth 
until  week  8  (Fig.  4  A).  The  production  of IP-10  from 
A549 and Calu  1 tumors was inversely correlated with tu- 
mor growth (r =  -0.648 and -0.688 for A549 and Calu 1 
tumors, respectively, P <0.05)(Fig. 4 B). In addition, IP-10 
levels were significantly higher in  the  Calu  1  (SCCA)  tu- 
mors,  as  compared  to  A549  tumors.  Plasma  IP-10  levels 
from  tumor-bearing  SCID  mice  paralleled  the  findings 
from the  primary  tumors  (data  not shown).  Furthermore, 
the  appearance  of spontaneous  lung  metastases  in  SCID 
mice beating A549 tumors occurred after IP-10 levels from 
either the primary tumor or plasma reached a nadir. To de- 
termine  whether  IP-10 in  vitro  was  an  autocrine  growth 
factor for these cell lines,  A549 and Calu  l  cells  were cul- 
tured in the presence or absence of recombinant IP-10 for 
24  and  48  h  (Table  1,  and  data  not shown,  respectively). 
The presence  of exogenous  IP-10  did  not  alter  prolifera- 
tion,  as compared to appropriate  controls  (P >0.2).  These 
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Figure 4.  Tumorigenesis  of human non-small cell lung cancer, adeno- 
carcinoma (A549) and squamous cell carcinoma (Calu-1), in SCID mice 
as it correlates to the production of tumor-derived IP-10. (A) Tumor 
g-rowth as measured by size (ram2). (B) the kinetics of tumor-derived 1P- 
10 as expressed as pg/mg of total protein (TP). 
findings suggested that IP-10 neither functions as an auto- 
crine growth factor nor an inhibitor of cellular proliferation 
of human NSCLC cell lines. 
The Presence of lntratumor IP-lO Attenuates or Absence qfl lP- 
10 Augments  Tumor Growth and Spontaneous Lung Metastases. 
Since  IP-10 was found to be a potent  endogenous anglo- 
static molecule in SCCA, the reduced expression  of IP-10 
in A549  (adenocarcinoma)  tumors, as compared to Calu  1 
(SCCA)  tumors,  may contribute  to  their  more  aggressive 
behavior. We hypothesized that restoration of tumor asso- 
ciated IP-10 in A549 tumors could lead to inhibition of tu- 
morigenesis  via  an  IP-10-dependent  decrease  in  tumor- 
associated angiogenic activity and neovascularization.  SCID 
mice bearing A549 tumors were injected (intratumor) with 
either recombinant human IP-10 (1  txg in 20 Ixl of normal 
saline) or 20 Ixl of an equimolar concentration of an irrele- 
vant human protein,  human serum  albumin  (HSA),  every 
48 h  for a period of 8  wk beginning at the time  of tmnor 
cell  inoculation.  The  intratumor  administration  of IP-10 
resulted  in  a  40%  and  42%  reduction  in  tumor  size  and 
mass,  respectively,  as  compared  to  tumors  treated  with 
intratumor  HSA  (0.79  _+  0.14  g  vs.  1.37  -4-  0.23  g  and 
986  IP-10 as an Endogenous Angiostatic Factor in Non-small Celt Lung Cancer Table 1.  Proliferation of NSCLC  Cell Lines (A549 and Calu  1) 
in the Presence or Absence of lP- l O  for 24 h 
Stimulation 
IP-10  0 ng/ml  1 ng/ml  10 ng/ml  100 ng/ml 
cells (104  ) 
A549  20 +- 4.0  36  +- 6.0  33  -+ 4.0  28 +- 4.0 
Calu 1  38  +  4.0  39  +  6.0  39  +  3.0  41  -+ 3.0 
136  _+  17  1111112 VS.  217  +  27  1111112 at 8  wk,  respectively, P 
~<0.03,  Fig. 5, A-C).  To  exclude that IP-10  inhibited tu- 
mor growth by recruiting tumoricidal leukocytes, quantita- 
tion of tumor-infiltrating leukocytes was performed. A549 
tumors  from  SClD  mice  treated  for  8  wk with  IP-10,  as 
compared to  HSA,  revealed no  evidence for alterations in 
intratumor  leukocyte  populations  (Fig.  6).  We  sought  to 
determine whether  IP-10  treatment  of the primary tumor 
also reduced spontaneous  lung metastases.  The  number  of 
metastases  was  significantly reduced  in  mice  treated  with 
IP-10, as compared with HSA (3.5  +  0.6 vs. 8.7  -+ 0.9 me- 
tastases per lung section, respectively, P  <  0.001, Fig. 7 A). 
In addition, the  size  (area)  of the  lung metastases per sec- 
tion  was  also  dramatically reduced  in  the  IP-10,  as  com- 
pared to the HSA treated mice  (37  +  13  X  103 vs.  142  + 
29  ￿  103  square  pixels, respectively, P  <  0.01,  Fig.  7  B). 
To further demonstrate the importance of endogenous IP- 
10  in  the  regulation  of human  NSCLC  (SCCA)  tumor 
growth,  we passively immunized SCID mice bearing Calu 
1 tumors with either neutralizing rabbit anti-human  IP-10 
or control antibodies for  10 wk.  Calu  1  tumors from ani- 
mals that were passively immunized with neutralizing anti- 
bodies to IP-10 for 10 wk demonstrated a  1.8-2.9-fold in- 
crease in tumor size, as compared to  tumors from animals 
that  had  received  control  antibodies  (data  not  shown). 
However,  there was no  evidence of lung metastases in ei- 
ther group. 
Reconstitution  of Intratumor  IP- 10 Attenuates  Tumor-associated 
Angiogenic Activity and  Vasculature.  To  further  determine 
the mechanism of growth inhibition by intratumor admin- 
istration of lP-10, we directly evaluated angiogenic activity 
from A549 tumors of animals that had been treated in vivo 
with either IP-10  or HSA for 8  wk.  The  previously well- 
characterized rat corneal micropocket assay of neovascular- 
Figure 5,  Intratumor injection of IP-10 inhibits growth of human adenocarinoma (A549) tumors in SCID mice. (A) IP-10-induced inhibition of tu- 
mor growth, as compared to tumors treated with human serum albumin (HSA). (13) The difference in tumor mass (grams) at 8 wk from tumors treated 
with either IP-10 or HSA. Tumor n = 12 at each tittle-point. (C-3 Representative photograph ofA549 tumor-beating mice treated with either intratumor 
injection of liSA or IP-10 for 8 wk. 
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Figure 6.  Tumor-associated  leukocyte (neutrophil or macrophage) in- 
filtration from A549 tumors treated with either intratumor injection of 
HSA or IP-10 for 8 wk. Leukocyte infiltration was expressed as the mean 
number ofleukocytes per high power field (200  ￿ 
B  Area of Metastatic  Lzmg Tmmc~s per sedion 
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Figure 7.  lntratumor  injection 
of IP-10 in primary human ade- 
nocarcinoma (A549) tumors in 
SCID mice inhibits spontaneous 
lung metastases. (A)  number of 
lung metastases in  mice treated 
with either HSA or IP-10 for 8 
wk.  The  number  of metastases 
was  expressed per  section  of 
lung. (/3) size of lung metastases 
m mice treated with either HSA 
or IP-10 for 8 wk.  The size of 
lung metastases was expressed as 
square pixels ￿  10  3. 
ization was employed (33,  35).  Tumor homogenates were 
normalized to total protein, incorporated into Hydron pel- 
lets,  and  embedded  into  the  normally avascular rat  cornea 
(Fig.  8).  9  of 12  A549  tumor samples  from  IP-10  treated 
tumors  induced  no  significant  corneal  neovascular  re- 
sponse,  with  the  remaining  3  inducing  only weak  angio- 
genic activity (Fig. 8, A-C). In contrast,  11  of 12 A549 tu- 
mor  samples  from  HSA  treated  tumors  induced  positive 
corneal  angiogenic  responses  (Fig.  8,  D--F).  Importantly, 
there was no infiltration of the corneal tissue by inflamma- 
tory cells  in any of the test samples, suggesting that the an- 
giogenic  responses  were  mediated  entirely  by  factors 
present in tumor tissue,  rather than by products of infiltrat- 
ing  inflammatory  cells.  To  further  confirm  that  the  de- 
creased  angiogenic  activity  correlated  with  a  reduction  in 
tumor vasculature, vessel density by FACS  |  analysis of Fac- 
tor  VIII-related  antigen  expressing  endothelial  cells  from 
the  primary  tumors  was  quantified  from A549  tumors  of 
SCID mice treated with  either intratumor  IP-10 or HSA, 
Tumor-derived  Factor VIII-related antigen  expressing en- 
dothelial  cells  were  markedly  reduced  in  primary  tumors 
treated  with  IP-10,  as  compared to  HSA (7.8  +  1.3% vs. 
32.4 +  8.7%, P  <0.05,  Fig. 9).  These studies demonstrated 
that IP-10 behaved as a potent angiostatic factor for the at- 
tenuation  of tumor-derived  neovascularization  leading  to 
reduced tumorigenicity and spontaneous metastases. 
Discussion 
In this study we demonstrated that IP-IO plays an impor- 
tant role in regulating the  angiogenic activity and  neovas- 
cularization  of human  NSCLC.  IP-10 is  a  member of the 
CXC  chemokine  family  (36).  In  monomeric  forms  the 
CXC  chemokine  family ranges  in  mass  from 7  to  10  kD 
and  are  characteristically  basic,  heparin-binding  proteins. 
These  chemokines  display four highly  conserved  cysteine 
amino  acid residues,  with  the  first  two  cysteines separated 
by a non-conserved amino acid residue  (37, 38). The CXC 
chemokines  are  all  clustered  on  human  chromosome  4 
(q12-q21)  and  exhibit  between  2{)  to  50%  homology on 
the  amino  acid level.  While  the  CXC  chemokine  family 
was  originally recognized  for their  leukocyte  chemotactic 
activity,  these  cytokines  can  also  behave  as  either  angio- 
genic or angiostatic factors depending upon the presence or 
absence,  respectively,  of a  three  amino  acid  motif,  Glu- 
Leu-Arg  (ELR  moti0  which  precedes  the  first  conserved 
cysteine amino  acid residue  in  the primary sequence  (25). 
For  example,  platelet  factor-4  (PF-4),  monokine  induced 
by interferon-gamma  (MIG),  and  IP-10 all  lack  the  ELR 
motif and  are  angiostatic  factors  (25,  39,  40).  In contrast, 
CXC chemokines that contain the ELR motif, such as in- 
terleukin-8  (IL-8), neutrophil activating protein-2  (NAP-2), 
growth-related  oncogene  alpha  (GRO-o  0,  GRO-[3, 
GRO-y, epithelial neutrophil activating protein-78 (ENA- 
78),  and  granulocyte  chemotactic protein-2  (GCP-2),  in- 
duce  angiogenic  activity  at  physiological  concentrations 
(25, 41-43). 
While the ELR motif appears  to be  an important struc- 
tural  domain  that  dictates  whether  CXC  chemokines  are 
angiogenic or angiostatic in their behavior, another charac- 
teristic,  in general,  distinguishes  these  two groups.  The in- 
terferons (IFN-o~, IFN-[3, and IFN-y) are all known inhib- 
itors  of wound repair,  especially  angiogenesis  (18,  44-48). 
988  IP-10 as an Endogenous Angiostatic Factor in Non-small Cell Lung Cancer Figure 8.  Intratumor injection of IP-10 in primary human adenocarcinoma (A549) tumors in SCID mice reduces their angiogenic  activity. A-C are 
representative of the rat corneal angiogenic responses to tumors that had been treated with intratumor IP-10 for 8 wk (25X). D-F are representative of 
the rat corneal angiogenic responses to tumors that had been treated with intratumor HSA for 8 wk (25X). 
These  cytokines  are  potent  agonists  for the  expression  of 
IP-10 from a  number of cells,  including keratinocytes,  fi- 
broblasts,  endothelial  cells,  and  mononuclear  phagocytes 
(20-23).  In contrast, IFN-ix, IFN-[3, and IFN-T are all po- 
tent inhibitors of the production of monocyte-derived IL-8, 
GRO-ot, and ENA-78 (49, 50), supporting the notion that 
IFN-0~,  IFN-13,  and  IFN-y may shift  the  local  biological 
balance of ELR- and non-ELR-CXC  chemokines toward 
a  preponderance  of angiostatic  (IP-10)  CXC  chemokines. 
These  findings  suggest  that interferon-y  can alter  the bal- 
ance  of expression  of angiogenic  and  angiostatic  CXC 
chemokines  which,  in  the  context  of tumorigenesis,  may 
be important in regulating net tumor-derived neovascular- 
ization. 
Angiogenesis is  necessary for growth of all  solid  tumors 
(5),  and the net neovacularization of a tumor is dependent 
upon an imbalance of the expression of angiogenic and an- 
giostatic factors (51).  Therefore,  the presence of an angio- 
static factor, IP-10, in the context of NSCLC is not unex- 
pected.  Other  angiostatic  factors  have  been  demonstrated 
to play an important role in the regulation of tumor-associ- 
ated angiogenesis.  O'Reilly and coworkers have described 
the  role  of an  inhibitor  of angiogenesis,  angiostatin,  in  a 
murine  model  of lung  cancer  (12).  These  investigators 
found that the production of angiostatin by the primary tu- 
mor was not only responsible for inhibition of tumorigene- 
sis within the primary tumor, but its presence in circulation 
was critical to the suppression of the growth of distant lung 
metastases.  In addition,  evidence has linked the downregu- 
lation  of the  local production  of angiostatic  factors to  the 
pathogenesis  and  evolution  of pre-malignant  to  malignant 
disease.  This  transition  to malignant growth has been asso- 
ciated with the activity of the tumor suppressor gene, p53, 
and its  relationship  to the angiostatic factor, thrombospon- 
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din-1.  These studies demonstrated that either loss or muta- 
tion of p53 results in a "switch" to a more angiogenic phe- 
notype  (11,  14),  that  coincides  with  the  downregulation 
and loss of the angiostatic activity attributable  to thrombo- 
spondin-1  (52). These findings demonstrate the importance 
of the endogenous expression ofangiostatic factors in regu- 
lating the  biology of malignant  tumor  growth.  Our find- 
ings for IP-10 are consistent with the above studies for an- 
giostatin  and  thrombospondin-1,  as  levels  of IP-10  from 
both  the primary tumor and plasma  were inversely  corre- 
lated  with  primary  tumor  growth  and  spontaneous  me- 
tastases  (A549 adenocarcinoma) to the lung of SCID mice. 
Moreover, the depletion oflP-10 from Calu  1 (SCCA) tu- 
mors resulted  in  their  augmented  growth,  whereas  recon- 
stitution of IP-10 in A549 (adenocarcinomas) tumors reduced 
their  tumorgenicity,  tumor-associated  neovascularization, 
and spontaneous metastases  to the lung.  This effect was at- 
tributable to IP-10 inhibition of  tumor-derived angiogenesis. 
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Figure 9.  Tumor-associated  endothelial cells, as expressed by the per- 
cent of Factor VIII-related  antigen positive cells by FACS  |  analysis. The  observation of a marked  difference in the levels of 
IP-10 associated with  SCCA,  as compared to adenocarci- 
noma, in freshly isolated NSCLC tumor specimens is patho- 
physiologically relevant  and  represents  a  possible  mecha- 
nism for the biologic differences of these two cell types of 
NSCLC.  Patient  survival  and  metastatic  potential  for 
NSCLC  are  significantly  different.  For  example,  patient 
survival is lower and metastatic potential is higher for ade- 
nocarcinoma,  as  compared  to  SCCA of the  lung  (4,  53). 
This  difference  may  be  due,  in  part,  to  the  greater  IP- 
10-dependent  angiostatic  activity found in freshly isolated 
SCCA  tumor specimens.  This  is  supported  by the  recent 
findings that SCCA specimens displayed less tumor-derived 
vasculature  than  adenocarcinomas  of the  lung  (54).  Our 
finding of higher levels  of IP-10 in freshly isolated  speci- 
mens of SCCA, as compared to adenocarcinoma,  demon- 
strate  a  potential  inverse  relationship  between  IP-10  and 
tumor vasculature,  which may explain the behavior differ- 
ences of SCCA vs. adenocarinoma. However, to establish a 
"cause and effect" relationship, we extended these observa- 
tions  and  employed a  strategy to  temporally  examine  the 
biology  of  IP-10  during  the  growth  and  metastasis  of 
NSCLC (adenocarcinoma vs. SCCA) in vivo. 
The  rationale  for  using  these  two  NSCLC  cell  lines 
(A549;  adenocarcinoma and  Calu  1;  squamous  cell  carci- 
noma) was based on both their previous use in immunode- 
ficient mice and their heterogeneous characteristics that in- 
clude:  tumorigenicity  (A549  >Calu  1)  (55);  spontaneous 
lung metastasis  (A549  >Calu  1)(55);  and  experimental  lung 
metastasis (A549 >Calu 1)  (55).  However, the secretion of 
metalloproteinases  and  tissue  inhibitors  of metalloprotein- 
ases  (56); expression of integrins  (57); or expression of mu- 
tants of the tumor suppressor gene, p53  (58)  all have failed 
to correlate with their tumorigenicity and ability to sponta- 
neously metastasize  (55-58). We found that the expression 
of IP-10 from either A549 or Calu 1 tumors inversely cor- 
related with tumor growth in vivo. The nadir of IP-10 in 
both of these tumor types was associated with a more rapid 
rate of growth of the primary tumor, as well as the appear- 
ance of spontaneous metastases ofA549 tumors in the lungs 
of SCID mice. 
To exploit the  differences in the  expression  of IP-10 in 
A549 and Calu 1 tumors and determine  the effect of alter- 
ing the biology of IP-10 on tumor growth, tumor-associ- 
ated angiogenic activity and neovascularization,  and spon- 
taneous  metastases,  we  used  a  strategy  of either  IP-10 
depletion  in  Calu  1  (SCCA)  tumors  or  reconstitution  in 
A549  (adenocarinoma)  tumors.  Although  we  did  not  ap- 
preciate  any  evidence  for  augmented  spontaneous  me- 
tastases  of Calu  1  tumors  in  SCID  mice  that  had  been 
treated  with  neutralizing  anti-lP-10  antibodies  for  10 
weeks,  we found that  the primary tumors were markedly 
larger in size, as compared to control antibody treated ani- 
mals. In contrast, intratumor administration of lP-10 signif- 
icantly  reduced  the  tumor  growth  and  spontaneous  me- 
tastases  of A549  tumors  without  evidence  for augmented 
recruitment of intratumor leukocytes. This effect was due to 
reduced  tumor-associated  angiogenic  activity and  neovas- 
cularization.  These  results  are in agreement with both the 
previous  findings  of the  anti-tumor  effects  of intratumor 
PF-4 (59)  or transfection of the gene for IP-10 (60). How- 
ever, this latter study found that the anti-tumor activity of 
IP-10 was T  cell-dependent, as tumors over-expressing IP-10 
failed to regress when engrafted in nude mice (60). In con- 
trast, we found in a model (SCID mice) that is both T  and 
B cell-independent,  that intratumor injection of IP-10 into 
a human NSCLC adenocarcinoma resulted in a striking re- 
duction  in  tumor-derived  angiogenic  activity  and  in  cells 
expressing Factor VIII-related antigen.  These  effects were 
unrelated  to  any  difference  in  tumor  infiltrating  popula- 
tions  of leukocytes.  The  difference  between  these  two 
studies  may be  related  to  our use  of human  NSCLC  cell 
lines as compared to nmrine tumor cell lines or the  use of 
SCID  vs.  nude  mice.  Thus,  our finding would  support  a 
non-immune function for IP-10 in the inhibition of tumor 
g-rowth. 
In  conclusion,  tumor-derived  angiogenesis  is  regulated 
by a dual, yet opposing, balance  of angiogenic and angio- 
static  factors.  The  magnitude  of the  expression  of angio- 
genic  and  angiostatic  factors  in  primary  tumors  correlates 
with  tumor  growth  and  spontaneous  metastases.  In  this 
study,  we  have  demonstrated  that,  in  the  context  of 
NSCLC, IP-10 is an important endogenous angiostatic fac- 
tor that regulates tumor growth, tumor-derived angiogenic 
activity and neovascularization, and potential for spontane- 
ous metastases.  These  findings support  the  notion  that  ei- 
ther  reconstitution  or  augnnentation  of the  expression  of 
IP-10 may be an important treatment strategy for NSCLC. 
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